Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.…
Innate Pharma stock tumbles after phase 1 trial data
Innate Pharma (NASDAQ: IPHA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 120 employees.
The shares were at 0.8634 USD on 20 November 2026, down 55.0% over 52 weeks. Its 52-week range is 0.8290 USD to 2.710 USD: the price is 68.1% below the high and 4.1% above the low.
Its market capitalisation is 96.44M USD.
Innate Pharma reports return on equity of 226.6%, an operating margin of -485.2% and revenue up 16.5% year over year.
Its debt exceeds its cash by 9.31M EUR. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.